IL17A and systemic sclerosis: In addition, applying a biomarker including low levels of IL-17, IL-12 and rheumatoid factor predicted response to RTX, suggesting that this “negative trial” could be indeed promising for RTX in a subset of patients with SSc-PAH (114).